Adam Taich, CFO of 10x Genomics (NASDAQ:TXG), sold 15,098 shares of Class A Common Stock on May 22, 2026. The transaction totaled $369,017 at $24.4415 per share.
The sale occurred as shares trade near their 52-week high of $26.45, following a 197% gain over the past year. The sale was to cover tax withholding obligations from vesting restricted stock units.
Following the transaction, Mr. Taich directly holds 379,898 shares. According to Bond.az analysis, the stock may be overvalued relative to its Fair Value.
In other news, William Blair upgraded the stock to Outperform, highlighting its role in AI-driven drug discovery. Bioptimus partnered with 10x Genomics to launch the Spatial Tissue Embedding Learning Atlas, profiling up to 100,000 tissue specimens.
ARK Invest sold over 473,000 shares, signaling a shift to gene-editing. Stifel raised its price target to $25 with a Buy rating, citing strong adoption of the Flex Apex product.
